Radar Therapeutics

Executive Summary

Radar Therapeutics is a preclinical-stage biotechnology company developing targeted radiotherapeutics for cancer treatment. Founded in 2020 and headquartered in the United States, the company has raised $13.4 million in funding to advance its pipeline of radiopharmaceuticals designed to deliver precise radiation to tumor cells while minimizing off-target effects. Radar Therapeutics focuses on combining novel targeting ligands with therapeutic radioisotopes, aiming to address unmet needs in oncology. As a private entity with 10-50 employees, the company is positioned to leverage the growing interest in radiopharmaceuticals, though it currently lacks public pipeline details or clinical-stage candidates. The success of Radar Therapeutics hinges on its ability to progress its lead programs toward the clinic and secure additional financing or partnerships to support development.

Upcoming Catalysts (preview)

• Q2 2027IND Submission for Lead Candidate60% success
• Q4 2026Strategic Partnership Announcement30% success
• Q3 2026Preclinical Data Presentation at Major Conference70% success